Atezolizumab and Recombinant Human Hyaluronidase for Non-Small Cell Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
USC / Norris Comprehensive Cancer Center, Los Angeles, CANon-Small Cell Lung Cancer+10 MoreAtezolizumab and Recombinant Human Hyaluronidase - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether atezolizumab, given at home via telemedicine, is safe and feasible for patients with non-small cell lung cancer.

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Stage IIB Lung Cancer
  • Stage IVB Lung Cancer
  • Stage III Lung Cancer
  • Stage IIIB Lung Cancer
  • Stage IVA Lung Cancer
  • Stage IIIA Lung Cancer
  • Stage II Lung Cancer
  • Stage IIA Lung Cancer
  • Stage IV Lung Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
1
Porfimer Sodium
1
Laboratory Biomarker Analysis

Study Objectives

2 Primary · 2 Secondary · Reporting Duration: Up to 2 years

Day 21
Healthcare provider and mobile nurse satisfaction with home administration of atezolizumab
Patient satisfaction with home administration of atezolizumab
Up to 2 years
Overall response rate
Progression free survival rate
Successful completion of home drug administration visits within the specified window
Day 30
Incidence of adverse events (AEs) of home administration by a healthcare provider (HCP) of subcutaneous atezolizumab

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
1
Porfimer Sodium
1
Laboratory Biomarker Analysis

Trial Design

1 Treatment Group

Treatment (atezolizumab and recombinant human hyaluronidase)
1 of 1

Experimental Treatment

37 Total Participants · 1 Treatment Group

Primary Treatment: Atezolizumab and Recombinant Human Hyaluronidase · No Placebo Group · Phase 2

Treatment (atezolizumab and recombinant human hyaluronidase)Experimental Group · 2 Interventions: Survey Administration, Atezolizumab and Recombinant Human Hyaluronidase · Intervention Types: Other, Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 2 years

Who is running the clinical trial?

University of Southern CaliforniaLead Sponsor
833 Previous Clinical Trials
1,431,363 Total Patients Enrolled
Genentech, Inc.Industry Sponsor
1,500 Previous Clinical Trials
565,055 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,153 Previous Clinical Trials
41,162,271 Total Patients Enrolled
Jorge J Nieva, MDPrincipal InvestigatorUniversity of Southern California
1 Previous Clinical Trials
75 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have stage II to IIIA lung cancer and have undergone surgery to remove the tumor, followed by chemotherapy containing platinum. Your tumor cells have at least 1% PD-L1 expression as determined by an FDA-approved test.
You must agree to sign a document saying you understand the study and agree to participate.
You are able to follow all the rules of the study, according to the doctor's opinion.
You have advanced cancer and your tumor shows high levels of PD-L1, as determined by an FDA-approved test. You do not have certain genetic mutations in your tumor.
You have advanced lung cancer that has continued to get worse after receiving platinum-containing chemotherapy. If you have certain genetic mutations, you should have also tried FDA-approved treatments for these mutations before joining the trial.
You must be 18 years old or older when you agree to participate in the study.
You have evidence of disease that can be seen on CT or PET scan.
You have a phone or computer with internet access.
You are able to perform daily activities with little to no difficulty.
You are expected to live for at least 3 more months.
References

Frequently Asked Questions

Do the benefits of Atezolizumab and Recombinant Human Hyaluronidase outweigh the risks?

"Atezolizumab and Recombinant Human Hyaluronidase's safety has been supported in some ways by data, but not efficacy. Thus, we have given it a score of 2." - Anonymous Online Contributor

Unverified Answer

Are participants being enrolled in this clinical trial at this time?

"No, the trial has stopped recruiting patients as of their last update on November 12th, 2022 according to information found on clinicaltrials.gov. The study was first posted December 5th, 2020. There are 2098 other trials that are still recruiting patients." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top